Bladder cancer patients who Can't take chemo may get new option
NCT ID NCT05241340
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of an immunotherapy drug called sasanlimab and focused radiation given before bladder removal surgery in 33 patients with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this approach is safe, feasible, and can eliminate cancer in the bladder at the time of surgery. The study is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sasanlimab (an immunotherapy drug) and stereotactic body radiation therapy (focused radiation)
What this could lead to
If successful, this combination could offer a new treatment option for bladder cancer patients who cannot receive standard chemotherapy, potentially improving outcomes before surgery.
What could go wrong
This is a small, early-phase trial with only 33 participants, so results may not apply to everyone. The treatment also carries risks of side effects from both immunotherapy and radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA BLADDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77006, United States